Deals this week: Orgenesis, Advanced Accelerator Applications, Kyowa Pharmaceutical

4 August 2016 (Last Updated August 4th, 2016 18:30)

Orgenesis INC has formed a joint venture (JV) with Atvio Biotech to provide gene and cell therapy development services.

Orgenesis INC has formed a joint venture (JV) with Atvio Biotech to provide gene and cell therapy development services.

According to the agreement, Orgenesis and shareholders of Atvio hold a 50-50 participating interest in the JV and Atvio will be responsible for providing contract development and manufacturing services for the global expansion of MaSTherCell, a wholly-owned subsidiary of Orgenesis.

Advanced Accelerator Applications S.A. and National Cancer Institute (NCI) have entered a co-development agreement to explore the additional indications for Lutathera in patients with inoperable pheochromocytoma and paraganglioma.

According to the agreement, NCI will be responsible to sponsor and conduct the study of Lutathera, while patients with pheochromocytoma and paraganglioma will be evaluated for the study at the National Institutes of Health.

Kyowa Pharmaceutical Industry, a subsidiary of Lupin Limited, has announced its acquirement of 21 products for therapy areas such as the central nervous system, oncology, cardiovascular and anti-infectives from Shionogi & Company Limited for a purchase consideration of $150m.

The transaction will enable Lupin to expand and strengthen its specialist business globally.

"Orgenesis INC has formed a joint venture (JV) with Atvio Biotech to provide gene and cell therapy development services."

INC Research Holdings INC. has announced an underwritten public offering of five million shares of its class A common stock. Wyrick Robbins Yates & pontoon LLP is acting as legal advisor for the offering.

The company has filed a registration statement with the US Securities and Exchange Commission (SEC) for the public offering of its shares in December 2015.

Bioniz Therapeutics has raised $13m in a series A venture financing round, which was co-led by Takeda Pharmaceutical Company Limited, Dr. David Pyott, Joe Kiani, and Cota Capital.

The company plans to invest the raised funds to advance its peptide platform technology mainly focused on the selective blockade of key cytokines in serious diseases.


Image: Advanced Accelerator Applications S.A. and National Cancer Institute (NCI) have entered a co-development agreement. Photo: Courtesy of NIH.